Monoclonal antibody · Antagonist of LIGHT (TNFSF14) (TNFSF14) · developed by Avalo Therapeutics
MDGN-002 is a fully human IgG4 monoclonal antibody that binds human LIGHT. It is being studied in Crohn disease and ulcerative colitis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03169894 | Phase 1 | Crohn Disease | Terminated | AVTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Crohn DiseaseUlcerative Colitis
Updated Nov 8, 2026. Something wrong or missing? Report it on the AVTX page.
See AVTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AVTX catalysts and pipeline →